Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy

Abstract Background The standard care for resectable non-small cell lung cancer (NSCLC) involves perioperative therapy combining chemotherapy and immune checkpoint inhibitors, typically lasting 6 to 12 months. However, the optimal treatment strategies for potentially resectable squamous cell lung ca...

Full description

Bibliographic Details

Published in:	BMC Medicine
Main Authors:	Jianzhen Shan, Zhen Liu, Songan Chen, Chengli Du, Bing Li, Lingxiang Ruan, Mei Kong, Lingjie Wang, Miaoyan Du, Shuo Shi, Guoliang Qiao, Tian Tian, Zhengliang Tu
Format:	Article
Language:	English
Published:	BMC 2024-06-01
Subjects:	Perioperative therapy Squamous cell lung carcinoma Major pathologic response Biomarkers Tislelizumab
Online Access:	https://doi.org/10.1186/s12916-024-03462-4